Thursday, July 9, 2026

Drug profile · INN

etonogestrel

etonogestrel (IMPLANON NXT) is a progesterone receptor agonist. Associated with Organon Pharma Pty Ltd. Route of administration: implantation. Current US regulatory status: approved.

FDA: approved TGA: approved
US status approved
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — etonogestrel
US status
approved
Class
Route
IMPLANTATION
Patents
0
Programs
2
Data quality
0.84

Quick answer

etonogestrel (IMPLANON NXT) is a progesterone receptor agonist. Associated with Organon Pharma Pty Ltd. Route of administration: implantation. Current US regulatory status: approved.

Key facts

INN etonogestrel
Brand IMPLANON NXT
Mechanism Progesterone receptor agonist
Target Progesterone receptor
Route IMPLANTATION
Formulation IMPLANT

Mechanism of action

Progesterone receptor agonist

Primary target: Progesterone receptor

Approval history

Authority Status Date
FDA approved
TGA approved

Pipeline programs

  1. BLCL-ETN-ANV-01 Phase 1 · Tillomed Laboratories · No medical condition
  2. BLCL-ETN-ANV-02 Phase 1 · Tillomed Laboratories · No medical condition.

Related & competitor drugs

  1. desogestrel Progesterone receptor agonist
  2. medroxyprogesterone acetate Progesterone receptor agonist
  3. megestrol acetate Progesterone receptor agonist
  4. norethindrone Progesterone receptor agonist
  5. norethindrone acetate Progesterone receptor agonist
  6. progesterone Progesterone receptor agonist

Frequently asked questions

What is etonogestrel?

etonogestrel (IMPLANON NXT) is a progesterone receptor agonist. Associated with Organon Pharma Pty Ltd. Route of administration: implantation. Current US regulatory status: approved.

What is the brand name for etonogestrel?

IMPLANON NXT is a marketed brand name for etonogestrel. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of etonogestrel?

etonogestrel has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.